HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Boldt, J. Articles by Hempelmann, G. Search for Related Content PubMed PubMed Citation Articles by Boldt, J. Articles by Hempelmann, G.

J Thorac Cardiovasc Surg 1994;107:1215-1221
© 1994 Mosby, Inc.

CARDIOPULMONARY BYPASS, MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

Influence of aprotinin on the thrombomodulin/ protein C system in pediatric cardiac operations

Giessen, Germany

Received for publication May 28, 1993. Accepted for publication Sept. 27, 1993. Address for reprints: Joachim Boldt, MD, Department of Anesthesiology and Intensive Care Medicine, Klinikstr. 29, Justus-Liebig-University Giessen, 35392 Giessen, Germany.

Abstract

Thirty consecutive children scheduled for pediatric cardiac operation with cardiopulmonary bypass were included in the study. Before the operation, the patients were randomly divided into two groups: with aprotinin (n = 15, 30,000 U/kg after induction of anesthesia, 30,000 U/kg added to the prime of the cardiopulmonary bypass system followed by additional 30,000 U/kg every hour until the end of cardiopulmonary bypass or without aprotinin (n = 15). Thrombomodulin, (free) protein S, protein C, and thrombin/antithrombin III complex were measured from arterial blood samples taken after induction of anesthesia (at baseline, before aprotinin) and before, during, and after cardiopulmonary bypass until the first postoperative day. Standard coagulation parameters (antithrombin III, fibrinogen, platelet count, and partial thromboplastin time) were without differences between the groups. Thrombomodulin plasma concentrations were within normal range (<40µg/L) and were similar in both groups at baseline. During cardiopulmonary bypass and until 5 hours after cardiopulmonary bypass, however, thrombomodulin plasma levels were significantly lower in the children treated with aprotinin. No further differences were observed on the first postoperative day. Protein C and protein S plasma levels did not differ between the two groups. Thrombin/antithrombin III–complex plasma concentrations increased significantly during cardiopulmonary bypass, however, without showing differences between children with (225 ± 49µg/L) and without (149 ± 31µg/L) aprotinin treatment. Blood loss and the need for homologous blood and blood products did not differ significantly between the two groups. We concluded that administration of aprotinin resulted in reduced thrombomodulin plasma levels in pediatric patients undergoing cardiac operation without altering protein C/protein S plasma concentration. The exact role of aprotinin in endothelium-derived coagulation should be further studied. (J THORAC CARDIOVASC SURG 1994;107:1215-21)

This article has been cited by other articles:

				M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]

				D. M. Arnold, D. A. Fergusson, A. K.C. Chan, R. J. Cook, G. A. Fraser, W. Lim, M. A. Blajchman, and D. J. Cook Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth. Analg., March 1, 2006; 102(3): 731 - 737. [Abstract] [Full Text] [PDF]

				J. M. Costello, C. L. Backer, A. de Hoyos, H. J. Binns, and C. Mavroudis Aprotinin reduces operative closure time and blood product use after pediatric bypass Ann. Thorac. Surg., April 1, 2003; 75(4): 1261 - 1266. [Abstract] [Full Text] [PDF]

				G. D. Williams, S. L. Bratton, E. C. Riley, and C. Ramamoorthy Association between age and blood loss in children undergoing open heart operations Ann. Thorac. Surg., September 1, 1998; 66(3): 870 - 875. [Abstract] [Full Text] [PDF]

				P. Pouard Review of Efficacy Parameters Ann. Thorac. Surg., June 1, 1998; 65(90060): S40 - 44. [Abstract] [Full Text] [PDF]

				H. Mossinger and W. Dietrich Activation of Hemostasis During Cardiopulmonary Bypass and Pediatric Aprotinin Dosage Ann. Thorac. Surg., June 1, 1998; 65(90060): S45 - 51. [Abstract] [Full Text] [PDF]

				J. Boldt Endothelial-Related Coagulation in Pediatric Surgery Ann. Thorac. Surg., June 1, 1998; 65(90060): S56 - 59. [Abstract] [Full Text] [PDF]

				D. Royston Hemostatic Drugs in Prothrombotic or Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394. [Abstract] [PDF]

				S. Cicek, U. Demirkilic, E. Kuralay, E. Ozal, and H. Tatar Postoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations Ann. Thorac. Surg., May 1, 1996; 61(5): 1372 - 1376. [Abstract] [Full Text]